Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
David C. D. Hope, Matthew L. Vincent, Tricia Tan
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 60

Showing 26-50 of 60 citing articles:

Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
Ronald Goldenberg, Jeremy Gilbert, Priya Manjoo, et al.
Obesity Reviews (2023) Vol. 25, Iss. 3
Closed Access | Times Cited: 12
Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy
David C. D. Hope, Tricia Tan
Peptides (2023) Vol. 162, pp. 170962-170962
Closed Access | Times Cited: 11
Revisiting the evolution of Family B1 GPCRs and ligands: Insights from mollusca
João C. R. Cardoso, Jennifer C. Mc Shane, Zhi Li, et al.
Molecular and Cellular Endocrinology (2024) Vol. 586, pp. 112192-112192
Open Access | Times Cited: 4
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
Unlocking the Multifaceted Roles of GLP-1: Physiological Functions and Therapeutic Potential.
Tohada M. AL‐Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, et al.
Toxicology Reports (2025) Vol. 14, pp. 101895-101895
Open Access
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri, Michael Charlton, Meagan Gray, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Perspectives in weight control in diabetes – Survodutide
Thomas Klein, Robert Augustin, Anita M. Hennige
Diabetes Research and Clinical Practice (2023) Vol. 207, pp. 110779-110779
Closed Access | Times Cited: 10
Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate meals
Konstantinos Stefanakis, Alexander Kokkinos, Stamatia Simati, et al.
Clinical Nutrition (2023) Vol. 42, Iss. 8, pp. 1369-1378
Closed Access | Times Cited: 9
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Franco Folli, Giovanna Finzi, Roberto Manfrini, et al.
AJP Endocrinology and Metabolism (2023) Vol. 325, Iss. 5, pp. E595-E609
Open Access | Times Cited: 9
An updated patent review of GLP-1 receptor agonists (2020-present)
Weiwen Lu, Zhongbo Zhou, Neng Jiang, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 9, pp. 597-612
Closed Access | Times Cited: 9
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial
David C. D. Hope, Saleem Ansari, Sirazum Choudhury, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1479-1491
Open Access | Times Cited: 3
Dual glucagon‐like peptide‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity
Rajna Golubić, Jane Kennet, Victoria Parker, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2634-2644
Open Access | Times Cited: 3
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
David C.W. Lau, Rachel L. Batterham, Carel W. le Roux
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 3, pp. 251-268
Open Access | Times Cited: 12
Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients
Thomas Monfeuga, Jenny Norlin, Anne Bugge, et al.
Molecular Metabolism (2023) Vol. 79, pp. 101850-101850
Open Access | Times Cited: 6
Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
Richard J. MacIsaac, Gary Deed, Michael C dʼEmden, et al.
Diabetes Therapy (2023) Vol. 14, Iss. 12, pp. 1997-2014
Open Access | Times Cited: 5
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Nayyar Iqbal, Philip Ambery, Jennifer Logue, et al.
Diabetes Research and Clinical Practice (2023) Vol. 199, pp. 110669-110669
Closed Access | Times Cited: 4
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Eleonora Panfili, Giulio Frontino, Maria Teresa Pallotta
Frontiers in Clinical Diabetes and Healthcare (2023) Vol. 4
Open Access | Times Cited: 4
The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies
Peng Jiang, Ying Zeng, Wen Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116485-116485
Open Access | Times Cited: 1
Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice
Tatiana Lopes, David C. D. Hope, José M. Ramos Pittol, et al.
Molecular Metabolism (2024) Vol. 89, pp. 102024-102024
Open Access | Times Cited: 1
Small molecules targeting selective PCK1 and PGC-1α lysine acetylation cause anti-diabetic action through increased lactate oxidation
Beste Mutlu, Kfir Sharabi, Jee Hyung Sohn, et al.
Cell chemical biology (2024)
Closed Access | Times Cited: 1
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
Sean Wharton, Carel W. le Roux, Mikhail Kosiborod, et al.
Obesity (2024)
Open Access | Times Cited: 1
Mucosal and hormonal adaptations after Roux-en-Y gastric bypass
Fauzi Feris, Alison Mcrae, Todd A. Kellogg, et al.
Surgery for Obesity and Related Diseases (2022) Vol. 19, Iss. 1, pp. 37-49
Open Access | Times Cited: 7
Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy – A review
J. Michael Conlon, Finbarr O’Harte, Peter R. Flatt
Peptides (2021) Vol. 147, pp. 170706-170706
Open Access | Times Cited: 9
Novel Drugs for Diabetes Therapy
Tim Heise
Handbook of experimental pharmacology (2022), pp. 415-438
Closed Access | Times Cited: 5

Scroll to top